Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases

Published:2013-09-03 Issue:8 Volume:38 Page:914-924
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Rinaudo-Gaujous M.¹,Paul S.¹,Tedesco E. D.²,Genin C.¹,Roblin X.²,Peyrin-Biroulet L.³

Affiliation:

1. Laboratoire d'Immunologie et d'Immunomonitoring; CIC CIE3; GIMAP EA3064; CHU de Saint-Etienne France

2. Service de Gastrologie-Entérologie-Hépatologie; CHU de Saint-Etienne France

3. Inserm U954 et Service de Gastroentérologie; CHU de Nancy France

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.12477/fullpdf

Reference58 articles.

1. Pharmacy and pharmacology of biosimilars;Krämer;J Endocrinol Invest,2008

2. Toward biosimilar monoclonal antibodies;Schneider;Nat Biotechnol,2008

3. The rise of the biosimilar;McCamish;Expert Rev Clin Pharmacol,2012

4. Controlling the cost of innovative cancer therapeutics;Malik;Nat Rev Clin Oncol,2009

5. 2010 report generic savings GPhA http://www.prescriptionaccess.org/2010_Report_Generic_Savings_GPhA.pdf

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease;Arab Journal of Gastroenterology;2024-08

2. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients;Crohn's & Colitis 360;2021-04-01

3. Challenges for biosimilars: focus on rheumatoid arthritis;Critical Reviews in Biotechnology;2020-10-11

4. Identification of highly potent and selective inhibitor, TIPTP, of the p22phox-Rubicon axis as a therapeutic agent for rheumatoid arthritis;Scientific Reports;2020-03-12

5. Assays used to assess biosimilarity of therapies for inflammatory bowel disease;Expert Opinion on Drug Discovery;2019-12-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3